NCT00889837View on ClinicalTrials.gov

Staccato Loxapine Pulmonary Safety in Patients With COPD

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Inhaled Loxapine

Staccato Loxapine, 10 mg x 2 doses, 10 hours apart

DRUG

Inhaled Placebo

Staccato Placebo, inhalations x 2 , 10 hours apart

Trial Locations (1)

29303

Spartanburg Medical Research, Spartanburg

Sponsors
All Listed Sponsors
lead

Alexza Pharmaceuticals, Inc.

INDUSTRY